Bessière F, Roccia H, Delinière A, et al. - Studies suggesting hydroxychloroquine alone or in combination with azithromycin as beneficial against SARS-CoV-2, have led to an increase in their off-label use for cases with COVID-19, including for those in intensive care units (ICUs). Researchers here investigated whether hydroxychloroquine with or without azithromycin is safe regarding QT interval in ICU cases with COVID-19. They assessed 40 cases with COVID-19 (median age, 68 years [IQR, 58-74 years]; 32 men [80%]) who received hydroxychloroquine (200 mg, twice a day, for 10 days) with or without azithromycin (250 mg, daily, for 5 days). Increase in QTc intervals was observed in more than 90% of cases that raises concerns about the widespread use of hydroxychloroquine, with or without azithromycin, to treat COVID-19 in settings where cases cannot be adequately monitored. This work highlights safety concerns regarding the use of hydroxychloroquine with or without azithromycin for cases with COVID-19, especially when both drugs are provided together. No baseline clinical factors were identified that could be linked with subsequent QT prolongation. In this cohort, close monitoring of cases (including continuous QTc interval monitoring, daily ECGs, and laboratory tests), which resulted in an interruption of these drugs for 17 cases (42.5%), may have averted further complications, including drug-induced torsades de pointes.